More on PML in patients treated with dimethyl fumarate

New England Journal of Medicine

Volumn 374, Issue 3, 2016, Pages 294-295

  Reich, Kristian ^a   Hartung, Hans Peter ^b   Lebwohl, Mark ^c  

^a Dermatologikum Hamburg   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUMARIC ACID DIMETHYL ESTER; IMMUNOGLOBULIN G ANTIBODY; FUMARIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

CLINICAL FEATURE; HERPES ZOSTER; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LYMPHOCYTOPENIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; VIRUS REACTIVATION; CHEMICALLY INDUCED; FEMALE;

FEMALE; FUMARATES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL;

EID: 84996538708     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1512228     Document Type: Letter

References (4)

1. Balak D, Hajdarbegovic E. PML in patients treated with dimethyl fumarate. N Engl J Med 2015; 373: 582-3.
2. Philipp S, Kokolakis G, Hund M, et al. Immunological changes in psoriasis patients under long-term treatment with fumaric acid esters: risk of Kaposi sarcoma occurrence? Eur J Dermatol 2013; 23: 339-43.
3. van Kester MS, Bouwes Bavinck JN, Quint KD. PML in patients treated with dimethyl fumarate. N Engl J Med 2015; 373: 583-4.
4. Nieuwkamp DJ, Murk J-L, van Oosten BW, et al. PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N Engl J Med 2015; 372: 1474-6.